NCT00624351 - Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease | Biotech Hunter

Enrollment

227

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

Epratuzumab

Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.

OTHER

Placebo

Phosphate-buffered Saline (PBS) infusion.

Trial Locations (53)

Unknown

Birmingham

Tucson

La Jolla

Los Angeles

San Leandro

Denver

Farmington

Aventura

Tampa

Baltimore

Brooklyn

Chapel Hill

Charlotte

Durham

Wilmington

Oklahoma City

Dallas

Arlington

Milwaukee

Brussels

Leuven

Curitiba

Goiânia

Porto Alegre

Rio de Janeiro

São Paulo

Sorocaba

Chai Wan

Shatin

Debrecen

Zalaegerszeg

Bangalore

Hyderabad

Ludhiana

Madurai

Manipal

Nagpur

Kaunas

Klaipėda

Vilnius

Elblag

Gmina Końskie

Lublin

Poznan

Torun

Barcelona

Santander

Valencia

Donetsk

Ivano-Frankivsk

Kiev

Lviv

Birmingham